GlassScriptPhysician profile
Michelle C Crank
NPI 1861601650
$10,793.90
in general payments reported to CMS, 2019-2025
37 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.30 · 2020: $1,515 · 2021: $1,671 · 2022: $1,508 · 2023: $1,854 · 2024: $2,186 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,929 · Consulting Fee: $66.19 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,928.61 |
| Consulting Fee | $66.19 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,071.42 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $983.08 | 2020-2025 | Airsupra, Fasenra, Tezspire |
| Octapharma USA, INC. | $929.54 | 2020-2024 | Panzyga, Cutaquig |
| Biocryst US Sales Co., LLC | $804.06 | 2022-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $758.98 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Csl Behring | $666.92 | 2020-2025 | Hizentra, Andembry |
| Pfizer INC. | $621.97 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $542.24 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $540.88 | 2020-2025 | Dupixent |
| Genzyme Corporation | $479.27 | 2020-2025 | |
| Amgen INC. | $460.46 | 2021-2025 | Tezspire |
| Optinose US, INC. | $401.54 | 2020-2025 | |
| Grifols USA, LLC | $387.80 | 2020-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Pharming Healthcare, INC. | $359.13 | 2020-2025 | Ruconest |
| Genentech USA, INC. | $303.72 | 2021-2025 | Xolair |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $230.88 | 2020-2024 | Auvi-Q |
| Ionis Pharmaceuticals, INC. | $139.14 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $130.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.30 | 2021-2023 | Airduo Digihaler |
| Blueprint Medicines Corporation | $113.68 | 2023-2025 | Ayvakit |
| Alk-Abello, INC | $98.27 | 2020-2023 | Grastek, Odactra, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $97.72 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.05 | 2019-2023 | Spiriva Respimat |
| Seqirus USA INC | $82.01 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Abbvie INC. | $76.03 | 2024 | |
| Adma Biomanufacturing LLC | $66.19 | 2024-2025 | |
| Shire North American Group INC | $41.27 | 2019 | |
| Phadia US INC. | $34.32 | 2022-2023 | Immunocap |
| Lilly USA, LLC | $30.81 | 2024-2025 | Ebglyss, Taltz |
| Invivyd INC | $23.92 | 2025 | Pemgarda |
| Organon LLC | $23.58 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $22.75 | 2023 | |
| Leo Pharma INC. | $16.99 | 2022 | |
| Gc Biopharma USA, INC. | $16.66 | 2025 | Alyglo |
| Mylan Pharmaceuticals INC. | $15.29 | 2020 | |
| Hikma Pharmaceuticals USA | $14.40 | 2024 | Ryaltris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Crank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.